Sodium Cromoglycate 2% Eye Drops is indicated for the prophylaxis and symptomatic treatment of allergic eye disorders, including: Vernal keratoconjunctivitis, Vernal conjunctivitis, Giant papillary conjunctivitis, Vernal keratitis, Allergic keratoconjunctivitis. After starting therapy, symptoms such as itching, tearing, redness, and discharge are usually relieved within a few days. However, in some cases up to 6 weeks may be required for optimal effect. Once improvement occurs, treatment should be continued as long as needed to maintain relief.

Sodium Cromoglycate 2% Eye Drops works by inhibiting the release of inflammatory chemical mediators from sensitized mast cells. It facilitates rapid phosphorylation of mast cell proteins and modulates allergic responses triggered by antigen–antibody interaction, thereby preventing the release of toxic or inflammatory mediators. The exact mechanism is not fully understood, but it primarily acts locally on the ocular mucosa. Only a very small amount (approximately 0.03%) is absorbed systemically. It prevents the release of mediators of Type-I hypersensitivity reactions, including histamine and slow reacting substance of anaphylaxis (SRS-A), after antigen–antibody binding has occurred. It does not block IgE binding or antigen interaction with IgE-bound mast cells; instead, it suppresses mediator release following this reaction. It also inhibits Type-III (late allergic, Arthus) reactions.

The usual dosage of Sodium Cromoglycate 2% Eye Drops in adults and children over 4 years of age or older is 1 or 2 drops in each eye 4-6 times daily at regular intervals. The recommended frequency of administration should not be exceeded. Patients should be advised that the therapeutic effects of Sodium Cromoglycate 2% Eye Drops depend on administration of the drug at regular intervals.

Sodium Cromoglycate 2% Eye Drops has no known clinically significant drug interactions.

This medicine is contraindicated in patients with known hypersensitivity to Sodium Cromoglycate or any of its ingredients.

The most common side effect is temporary eye stinging or burning sensation immediately after application.

Animal studies show adverse fetal effects only at high parenteral doses. No evidence of fertility impairment has been observed in animal studies. Although healthy infants have been born to women who used Sodium Cromoglycate during pregnancy, safety in human pregnancy is not fully established. It should be used only if clearly necessary. It is not known whether the drug passes into breast milk; therefore, caution is advised during breastfeeding.

This medicine contains benzalkonium chloride, so soft contact lenses should not be used during treatment.

Overdose is unlikely. If accidentally ingested, symptomatic treatment should be given.

Mast cell stabiliser, ophthalmic non-steroidal drugs

Protect from direct sunlight and store below 30°C. Discard any unused solution 4 weeks after opening.